mTORC2信号通路与多发性骨髓瘤的研究进展  

Advance in Research on the Relationship between mTORC2 Signaling Pathway and Multiple Myeloma

作　　者：张亚男[1] 傅云峰[1] 刘竞[1] 

机构地区：[1]中南大学湘雅三医院血液内科,湖南长沙410013

出　　处：《中国医药指南》2014年第12期54-56,共3页Guide of China Medicine

摘　　要：多发性骨髓瘤目前仍是一种无法治愈的造血系统恶性肿瘤。近年来随着蛋白组学等生物技术的发展,对多发性骨髓瘤的发病机制有了更深入的认识,从而提出更侧重于微环境和细胞因子网络的靶向治疗。最近肿瘤生物学研究表明,雷帕霉素靶蛋白复合物2(mTORC2)的活性对一些肿瘤细胞的转移和活力起着至关重要的作用,却对正常细胞无影响,且关于mTORC2及其功能调控仍存在许多悬而未决的问题。本文就mTORC2信号通路和多发性骨髓瘤的靶向治疗前景作一综述。Multiple myeloma remains an incurable hematopoietic malignancies. In recent years, with the development of proteomics technology, more in-depth understanding of the pathogenesis of MM has been put forward, which focuses more on the microenvironment and cytokine network in the targeted therapy. Recent studies in cancer biology indicate that mTORC2 activity is essential for the transformation and vitality of a number of cancer celltypes, but in many normal cells, mTORC2 activity is less essential. However, there are many open questions regarding the function and regulation of mTORC2 and its function in both normal and cancer cells. Here, we summarize exciting new research into the biology of mTORC2 signaling and highlight the current state and future prospects for mTOR-targeted therapy on MM.

关 键 词：mTORC2信号通路 多发性骨髓瘤 MTOR抑制剂 

分 类 号：R733.3[医药卫生—肿瘤]